Patient characteristics impacting health state index scores, measured by the EQ-5D of females with stress urinary incontinence symptoms

Value in Health

Volumn 13, Issue 1, 2010, Pages 112-118

  Tincello, Douglas ^a   Sculpher, Mark ^b,c   Tunn, Ralf ^d   Quail, Deborah ^e   Van Der Vaart, Huub ^f   Falconer, Christian ^g   Manning, Martina ^h   Timlin, Louise ^e  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ICON PLC   (United Kingdom)

^d St Hedwig Hospital   (Germany)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g KAROLINSKA INSTITUTE   (Sweden)

^h LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

EQ 5D; Outcomes research; Patient reported outcomes; Women's health

Indexed keywords

DULOXETINE;

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GERMANY; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTICENTER STUDY; OBESITY; OUTCOME ASSESSMENT; PATIENT CARE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL STATUS; STRESS INCONTINENCE;

EID: 72949108715     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00599.x     Document Type: Article

References (26)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49.
2. Hunskaar S, Burgio K, Diokno A, et al. Epidemiology and natural history of urinary incontinence in women. Urology 2003 62 (Suppl. 1 S16 23. (Pubitemid 41116578)
3. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int 2004 93 : 324 330.
4. Vandoninck V, Bemelmans BL, Mazzetta C, et al. The prevalence of urinary incontinence in community-dwelling married women: a matter of definition. BJU Int 2004 94 : 1291 1295.
5. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 2000 53 : 1150 1157.
6. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998 46 : 473 480.
7. Incontinence, Third International Consultation on Urinary Incontinence (Vol. 2). Plymouth : Health Publication Ltd., 2005.
8. Sykes D, Castro R, Pons ME, et al. Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries. Maturitas 2005 52 (Suppl. 2 S13 23.
9. Papanicolaou S, Espuña-Pons M, Hampel C, et al. Prescribed medication for the treatment of women with urinary incontinence in Germany, Netherlands, Spain, Sweden and the United Kingdom. Results from PURE (Prospective Urinary incontinence REsearch). IUGA 2005. 2009.
10. Viktrup L, Bump RC. Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin 2003 19 : 485 490.
11. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002 187 : 40 8.
12. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003 170 (4 Pt 1 1259 1263.
13. Millard RJ, Moore K, Rencken R, et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004 93 : 311 318.
14. Van KP, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004 111 : 249 257.
15. Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004 104 : 511 519.
16. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001 4 : 225 250.
17. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 35 : 1095 1108.
18. MVH Group. The Measurement and Valuation of Health. Final Report on the Modelling of Valuation Tariffs. York, UK : York Centre for Health Economics, 1995.
19. Szende A, Williams A (eds.). Measuring Self-Reported Population Health: An International Perspective based on EQ-5D. Hungary : SpringMed Publishing Ltd., 2004.
20. Bent AE, Gousse AE, Hendrix SL, et al. Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence. Obstet Gynecol 2005 106 : 767 773.
21. EuroQol Group. EUROQol. Available from: http://www.euroqol.org/web/ [Accessed November 11, 2004
22. Hunskaar S, Lose G, Sykes D. Assessment of bothersomeness and impact on quality of life of urinary incontinence in women in France, Germany, Spain and the UK. BJU Int 2005 96 : 831-838.
23. Monz B, Chartier-Kastler E, Hampel C, et al. Patient characteristics associated with quality of life in European women seeking treatment for urinary incontinence: results from PURE. Eur Urol 2007 51 : 1073 1081.
24. Monz B, Hampel C, Porkess S, et al. A description of health care provision and access to treatment for women with urinary incontinence in Europe - a five-country comparison. Maturitas 2005 52 (Suppl. 2 S3 12.
25. Monz B, Pons ME, Hampel C, et al. Patient-reported impact of urinary incontinence - results from treatment seeking women in 14 European countries. Maturitas 2005 52 (Suppl. 2 S24 34.
26. Organisation for Economic Co-operation and Development. OECD Health Data 2004 (2nd ed.). OECD Publishing, 2009. CD-Rom Available from: http://www.oecd.org [Accessed November 1, 2006 ].